Author:
González Carmen Guadalupe Rodríguez,Vega Esther Chamorro de,Martínez Sofía De la Villa,Minero Maricela Valerio,Urbón José María Gutiérrez,Manzorro Álvaro Giménez,Martínez Edurne Fernández de Gamarra,Sacristán Sara Cobo,Santiago Emilio Bouza,Alonso Ana Herranz,Paredes Patricia Muñoz García de,Sáez María Sanjurjo
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Medicine
Reference21 articles.
1. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint;Wise;J Antimicrob Chemother,2001
2. European Public Assessment reports: Cubicin. London: European Medicines Agency. Available from: 〈https://www.ema.europa.eu/en/medicines/human/EPAR/cubicin〉 Accessed 20 December 2020.
3. Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections;Gonzalez-Ruiz;Infect Drug Resist,2016
4. High-dose daptomycin and clinical applications;Jones;Ann Pharmacother.,2021